Welcome to our dedicated page for WORK Medical Technology Group SEC filings (Ticker: WOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The WORK Medical Technology Group LTD (WOK) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a foreign private issuer in the medical devices sector. WORK Medical files annual reports on Form 20-F and current reports on Form 6-K, detailing its operations in developing and manufacturing Class I and II medical devices and selling Class I and II disposable medical devices through subsidiaries in China.
In these filings, investors can review information on WORK Medical’s product portfolio of medical consumables and equipment, its sales footprint across 34 provincial-level administrative regions in China, and the registration of 17 products with the U.S. Food and Drug Administration. Form 6-K reports provide updates on interim financial statements and management’s discussion and analysis, extraordinary general meetings and voting results, changes in independent auditors, and capital markets transactions such as registered direct offerings, at-the-market sales agreements, and pre-funded warrants.
Filings also describe share structure changes and Nasdaq listing matters, including approved share consolidations (reverse stock splits), increases in authorized share capital, and correspondence with Nasdaq regarding minimum bid price compliance and potential delisting determinations. These documents outline the reasons for share consolidations, effective dates, and post-consolidation share counts, giving context to changes in the company’s capital structure.
On Stock Titan, users can access WORK Medical’s Forms 6-K and 20-F as they are furnished to the SEC’s EDGAR system, along with AI-powered summaries that highlight key points such as financing terms, governance changes, and listing status updates. The filings page is also a reference point for tracking any future registration statements, prospectus supplements, and other transactional documents that the company incorporates by reference into its shelf registration statements.
HRT Financial LP, a ten percent owner of WORK Medical Technology Group, reported an open-market sale of 3,463,022 shares of Common Stock at $0.105 per share. After this transaction, HRT Financial LP reported holding zero shares directly.
WORK Medical Technology Group LTD disclosure: Kelly Habbas beneficially owns 369,000 Class A Ordinary Shares, representing 21.5% of the class, and reports sole voting and sole dispositive power over those shares. The filing is dated 06/10/2026.
HRT Financial LP, a ten percent owner of WORK Medical Technology Group LTD (WOK), reported an open-market purchase of 2,261,118 shares of Common Stock. The shares were bought at a price of $0.106 per share. After this transaction, HRT Financial LP directly holds 2,647,299 Common Stock shares.
WORK Medical Technology Group LTD filing an Amendment No. 1 to a Schedule 13G/A reporting that Trillium Trading, LLC beneficially owns 0 shares of Class A Ordinary Shares (CUSIP G9767H125), representing 0% of the class. The filing is signed by a compliance officer on 06/09/2026 and states the holder has no voting or dispositive power.
HRT FINANCIAL LP, a ten percent owner of WORK Medical Technology Group LTD (WOK), reported open-market purchases of a combined 1,424,537 shares of Common Stock. The firm bought 1,370,008 shares at $0.105 on June 4 and 54,529 shares at $0.093 on June 5, bringing its reported direct holdings to 386,181 shares.
WORK Medical Technology Group LTD disclosed that HRT FINANCIAL LP is a ten percent owner and reported holdings of 331,652 shares of Common Stock on an initial Form 3. This filing records HRT Financial LP’s existing ownership position rather than a new purchase or sale.
Trillium Trading, LLC reported beneficial ownership of 220,000 Class A Ordinary Shares of WORK Medical Technology Group LTD, representing 18% of that class per this Schedule 13G. The filing states Trillium has sole voting and sole dispositive power over 220,000 shares. The filing lists issuer headquarters in Auckland, New Zealand.
WORK Medical Technology Group LTD reported two strategic initiatives. The company formed a wholly owned U.S. subsidiary, Work Bio Technologies Ltd in Nevada, which is intended to become its primary operational platform in the United States, improving supply-chain management and direct business development with U.S. partners.
The company also participated as a partner and exhibitor at the 2026 CBA-China Annual Conference in Wuxi, engaging global biopharmaceutical experts on supply chain collaboration and AI in life sciences. WORK Medical highlighted its move into the “AI+Digital Healthcare” space as part of its long-term international growth strategy.
WORK Medical Technology Group LTD reported a Schedule 13G filing showing Kelly Habbas beneficially owns 325,000 Class A Ordinary Shares. The filing states Habbas has sole voting and dispositive power over 325,000 shares, representing 18.9% of the class. The filing was signed on 06/04/2026 and includes a commentary that the filing was late due to lack of EDGAR credentials; the filer applied for access and filed promptly upon receiving credentials.
HRT Financial LP, a ten percent owner of WORK Medical Technology Group LTD, reported mixed trading in Common Stock. On June 1, it made an open-market purchase of 2,746,332 shares at $0.138 per share. On June 2, it made an open-market sale of 1,757,955 shares at $0.107 per share, for a net purchase of 988,377 shares overall.